ICH E6(R3) reframes good clinical practice around quality by design and proportionate, risk-based thinking. Most of the commentary has focused on what this means for processes and documentation. The more interesting question is what it asks of the people leading clinical programs.
The revision assumes judgment. It moves away from prescriptive uniformity and toward decisions that are reasoned, documented, and defensible in context. A sponsor is expected to identify what matters most to participant safety and data reliability in their specific trial, and to allocate attention accordingly. That is a leadership act, not a checklist exercise.
This creates a real development gap. A generation of clinical operations professionals was trained to execute standard approaches consistently, with 100 percent source data verification as the default and deviation from the standard treated as a risk. E6(R3) asks those same professionals to defend why a particular level of oversight is appropriate for a particular trial. Those are different intellectual habits, and the second one has to be built.
Three capabilities deserve deliberate attention.
The first is critical-thinking about risk. Leaders need to reason from protocol design to the specific data and processes that determine whether the trial can answer its question. That reasoning has to be structured enough to write down and explain to an inspector.
The second is comfort with documented judgment. Many clinical professionals are reluctant to record a decision that might later be questioned. E6(R3) effectively requires it. The rationale is as important as the conclusion, and a well-reasoned decision that turned out imperfectly is defensible in a way an undocumented one is not.
The third is cross-functional fluency. Quality by design starts at protocol development, which means clinical operations leaders need to engage meaningfully with medical, biostatistics, and data management before the protocol is final. Leaders who only appear after finalization have lost their best opportunity to influence trial quality.
Sponsors treating E6(R3) as a documentation update will comply on paper. Sponsors treating it as a development agenda for their clinical leaders will run better trials.
What E6(R3) asks of leaders shows up first in how vendors are selected and governed. See CRO SELECTION AND OVERSIGHT.
